Crescendo Biologics Limited Email Format

Biotechnology ResearchEngland, United Kingdom2-10 Employees

Crescendo Biologics Limited is a private biotechnology company based in Cambridge, England, focused on immuno-oncology research and development. It develops novel, targeted T cell–enhancing Humabody therapeutics using a transgenic mouse platform that produces fully human VH domain building blocks (Humabody VH) to enable configurable engagement of therapeutic targets. The company’s lead programs include CB307, a half-life extended CD137 x PSMA Humabody designed to selectively activate tumour-specific T cells within the tumour microenvironment, and CB693, a half-life extended CD137 x MSLN Humabody; CB213 is a preclinical PD-1 x LAG-3 multi-specific Humabody. In addition to its proprietary pipeline, Crescendo maintains multi-target discovery collaborations with Takeda and BioNTech and holds an exclusive worldwide license with Zai Lab for ZL-1102 (formerly CB001), an anti-IL-17A Humabody expected to enter global Phase 2 development for psoriasis. The company operates with a small team (2-10 employees) and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda, and Quan Capital.

Get verified Crescendo Biologics Limited emails free

Company overview Employee directory